Biochemical and Morphological Abnormalities in Paranoid and Nonparanoid Schizophrenia

  • Ryo Takahashi


The understanding of the biological mechanism of schizophrenia has progressed during the past three decades since the advent of antipsychotic drugs. However, the biochemical findings of the dopamine system in the central nervous system of the patients are still inconsistent. One reason for this gap is, of course, that schizophrenia itself could be a heterogeneous condition. Therefore, subjects for biological study should be chosen to represent as homogeneous a group as possible. In this sense, patients with paranoid schizophrenia form a representative group to study from the biological point of view.


Negative Symptom Chronic Schizophrenia Paranoid Schizophrenia Interhemispheric Fissure Fisher Exact Probability Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Carlsson, B. E. Roos, J. Walinder, and A. Scott, Further studies on the mechanism of antipsychotic action., Potentiation by alpha-methyl-tyrosine of thioridazine effects in chronic schizophrenia, J. Neuronal Transmission., 34: 125 (1973).CrossRefGoogle Scholar
  2. 2.
    R. Takahashi, S. Yoshimoto, and H. Matsumoto., Implication of plasma level of neuroleptics in the treatment and pathophysiological research of schizophrenia, in:“Cooperation Franco-Japonaise,. Colloque Psychopharmacologie,” P. Pichot, T. Kobayashi eds., Paris (1979).Google Scholar
  3. 3.
    R. J. Wyatt, S. G. Potkin, T. P. Bridge, B. H- Phelps, and C. D. Weise, Monoamine oxidase in schizophrenia, And overview, Schizophrenia Bulletin. 6: 199 (1980).PubMedCrossRefGoogle Scholar
  4. 4.
    S. G. Potkin, H’ E. Cannon, D. L-. Murphy, and R. J. Wyatt, Are paranoid schizophrenics biologically different from other schizophrenics? The New Eng. J. Med. 298: 61 (1978).CrossRefGoogle Scholar
  5. 5.
    S. G. Potkin, K. Farouk, L. Chuang, H. E. Cannon-Spoor, L. Phillips, and R. J. Wyatt, Phenylethylamine in paranoid chronic schizophrenia. Science 206: 470 (1979).PubMedCrossRefGoogle Scholar
  6. 6.
    R. Takahashi, Y. Inaba, K. Inanaga, N. Kato, H. Kumashiro, T. Nishimura, T. Okuma, S. Otsuki, T. Sakai, T. Sato and Y. Shimazono, CT scanning and the investigation of schizophrenia, in:“Biological Psychiatry 198,” C. Perris, G. Struve and B. Jansson, eds., Elsevier, Amsterdam (1981).Google Scholar
  7. 7.
    T. J. Crow, Molecular pathology of schizophrenia; more than one disease process, Br. Med. J., 280: 66 (1980)-;PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Ryo Takahashi
    • 1
  1. 1.Department of NeuropsychiatryTokyo Medical and Dental UniversityYushima, Bunkyo-ku, TokyoJapan

Personalised recommendations